Blueprint Medicines

Do you know the difference between a mast cell-dependent disease and a mast cell-associated disease? Mast cell-dependent diseases are directly driven by the proliferation and activation of mast cells, which trigger other immune cells and exacerbate disease. For mast cell-associated diseases, mast cells are involved in the disease but not the sole pathogenic driver. We're building on our demonstrated expertise in mast cell biology with the goal of impacting patients across multiple diseases.

Our expanded scientific approach brings a new perspective to cracking the code of allergic and inflammatory diseases. Historically, most therapeutic approaches have focused on targeting mast cell mediators, stimulators or activators after they are released. We are pioneering an approach to target the mast cell itself as the central effector of these diseases, inhibiting activation and degranulation at the source. By combining our mast cell expertise and new technologies such as artificial intelligence and machine learning, we commit to delivering innovation with the potential for life-changing impact. Read more from Fouad Namouni, President of Research and Development:

In our commitment to corporate social responsibility, we’re dedicated to partnering with local non-profits to dismantle social barriers that may stand in the way of a full, healthy life. Catie's Closet, Inc helps provide school children with clothing and essential items, giving them the confidence to focus on their education and well-being instead of access to basic needs. Through this partnership and our sponsorship of Joseph Lee School in Boston, we’re working to bridge systemic disparities and help students thrive. Together, we're creating opportunities for young people in our communities to succeed without limitations. Read more in this blog: https://bit.ly/4hUiXQX

When we live our Patients First core value, we maintain an intense focus on improving patients’ lives. Across our Commercial Team, our #BlueCrew works tirelessly to educate healthcare professionals and support patient access to our innovation. Read how Chris Sloan and Cammy Hill incorporate this value into their work on our Market Access and Sales teams:

We’re proud to be named a Top 100 Healthcare Technology Company for 2024 by The Healthcare Technology Report, following our Chief Commercial Officer Philina Lee's recognition as a Top 25 Biotech Executive earlier this year. We've worked to hone our research platform that enables agile and cutting-edge drug discovery, empowering us to tackle complex medical challenges. Thank you to our #BlueCrew for your commitment to improving patients' lives every day. 

Recently, the #BlueCrew had a great time hosting Cancer Support Community Massachusetts’ annual fundraiser. We're committed to the local Boston community of patients and families, and we're proud to support this organization that delivers resources, financial counseling, and well-being assistance to people impacted by cancer.

At Blueprint Medicines, we are committed to encouraging new and diverse talent to enter the life sciences industry. Last week, Christopher Murray attended the American Chemical Society's second LEADS Conference, which connects distinguished scientists with aspiring scientific professionals looking to start their careers in chemical sciences. Below, read a few highlights from Chris from the conference and insights about a scientific career:

This month, members of our #BlueCrew attended annual conferences for Women of Color in Pharma (WOCIP) and Young Black Pharma, two groups that work to elevate the voices of people of color in the life sciences industry. We're committed to investing in development opportunities for people from marginalized or underrepresented communities, ensuring diverse talent across the #BlueCrew is celebrated and everyone has access to professional development opportunities.

Last month, our CEO Kate Haviland attended the National Organization for Rare Disorders Breakthrough Summit with over 900 members of the rare disease community. Kate joined a panel with other biotech CEOs and senior leaders to discuss how to support access to rare disease treatments. We strive to improve outcomes for people around the world by delivering innovative therapies that meet their clinical needs and positively impact their lives. #NORDSummit Read more from Kate below:

On November 14, we’re hosting an educational scientific seminar with renowned expert Paul O'Byrne to discuss how we plan to further develop our mast cell disease portfolio. Our industry-leading expertise in mast cell biology combined with our innovative research engine enables an agile approach, as we seek to address larger patient populations with high medical needs. Learn more: https://bit.ly/3ClSueJ